Additionally , TRO40303 was investigated in a Phase I randomized , double-blind , placebo controlled study to assess the safety , tolerability and pharmacokinetics of single intravenous ascending doses of the compound ( 0.5 to 13 mg/kg ) in 72 healthy male , post-menopausal and hysterectomized female subjects at flow rates from 0.04 to 35 mL/min ( EudraCT number : 2010-021453-39 ) .